Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet-Reference-Cited by-同舟云学术

Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet

Published:2019-05-30 Issue:3 Volume:60 Page:728-735
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Kimura Tomonari¹,Nakamura Kazufumi¹,Miyoshi Toru¹,Yoshida Masashi²,Akazawa Kaoru¹,Saito Yukihiro¹,Akagi Satoshi¹,Ohno Yuko¹,Kondo Megumi¹,Miura Daiji¹³,Wada Jun⁴,Ito Hiroshi¹

Affiliation:

1. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

2. Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

3. Department of Basic Medicine, Nagano College of Nursing

4. Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/60/3/60_18-392/_pdf

Reference34 articles.

1. 1. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.

2. 2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med 2015; 373: 2117-28.

3. 3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med 2017; 377: 644-57.